Compare Duke Energy Corp (DUK) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Duke Energy Corp trades at $116.8 (market cap $91.10B), while Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B). The key difference: Duke Energy Corp is the larger of the two by market cap, and Duke Energy Corp pays the higher dividend (3.71%). Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| DUK | REGN | |
|---|---|---|
Market Cap | $91.10B | $76.14B |
Volume | 4,199,050 | 500,239 |
Sector | Utilities | Health |
52-Week High | $133.46 | $852.03 |
52-Week Low | $113.23 | $557.73 |
Typical Hold Time | 74 Days | 107 Days |
Enterprise Value | $183.61B | $70.85B |
Dividend Yield | 3.71% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $115.5, down 0.14% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $28.8B in 2022 to $32.2B in 2025, and a net income margin of 15.78%. Recent news highlights dividend stability and data center-driven growth opportunities, though rising Treasury yields pressure utility stocks.
DUK offers a balanced outlook with steady dividends and growth from data center demand, but faces risks from high debt levels and interest rate sensitivity. Analyst consensus is mixed with a $135.33 price target, suggesting 17% upside, supported by a 43.75% buy rating. Investors should weigh solid profitability against macroeconomic headwinds.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
